Premium Structural Biology & Lead Discrovery Services

SARomics Biostructures provides premium structural biology and structure-based drug discovery services to the biotech industry and academic institutions. We have many years of experience and proven excellence in protein production, biophysical characterization and crystallization, protein X-ray crystallography and BioNMR spectroscopy, fragment screening, and fragment-based lead generation.

Please visit the "about" pages for additional company information. For details on the experimental methods, visit our technology platform overview. For the details of our services, follow the links below.

You may also
contact us directly for a company presentation and project discussion.
Click here for latest blog posts

Download some case studies based on published work.

Structural Biology Services

Our protein X-ray crystallography services provide protein crystallization and X-ray structure determination, FastLane™ Premium and FastLane™ standard libraries of verified drug targets (off-the-shelf structures), protein production and custom gene-to-structure and protein-ligand complex X-ray structure determination.
We provide a broad range of custom NMR (BioNMR) spectroscopy services that include peptide, protein, protein-ligand & protein-protein complex NMR assignment and 3D structure determination, NMR fragment screening using 1D or 2D NMR, epitope mapping and dissociation constant (Kd) determinations for compounds.
Antibody and antibody-antigen complex crystallization and high resolution X-ray structure determination, BioNMR and crystallographic characterization of higher order structure (HOS) of biosimilars, comparison with originator antibody and formulation optimization, biophysical characterization of antibodies and biosimilars in solution.

Lead Discovery Services

Integrated lead discovery and structure-based drug design (SBDD) include fragment screening, hit identification, hit-to-lead and lead optimization services, proprietary fragment library, and weak-affinity chromatography screening.
High throughput (2000-3000 cmpds/week), robust and accurate (validated against NMR and X-ray) fragment screening using weak-affinity chromatography (WAC™), which also includes binding assay and measurement of fragment affinity to immobilized protein - all in one experiment!
Protein optimization and structure-based design of biological drugs (biologics) and peptides using quantitative structure-activity relationships (QSAR) methodology as implemented in our proprietary ProPHECY™ protein optimization software package.

State-of-the-art Structural Biology Technology Platform

Our technology platform is equipped with state-of-the-art instrumentation for structural biology services, including protein production, robotic nanoliter-scale crystallization screening and optimization of conditions for crystal growth, and crystallization drop imaging. For X-ray crystallographic data collection, we use the MAX IV synchrotron radiation facility (image above), located a couple of kilometers from our labs in Lund. Alternatively, we send the crystals to other European synchrotrons. We collect X-ray data approximately every second week.

For NMR spectroscopy services, we have access to high-quality, cutting-edge instrumentation. We provide de novo NMR protein structure determination, protein-ligand/protein-protein complex NMR structure determination, small molecule fragment library screening, and much more…

You may use the form below to
contact us if you have questions about our structural biology services platform.
Maria Håkansson and Raymond Kimbung, protein crystallization facility  at SARomics Biostructures

Latest news and blog posts

What makes a successful CRO?

Looking back and analyzing our experience, the question we discuss here is, what makes a successful structural biology services company? What is our strength, and how to define our selling points? We arrive at a list of 8 essential selling points defining the success of SARomics Biostructures. Read more…

Aqilion's research alliance with Merck worth €950 million

First-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program made possible by combining X-ray crystallography and medicinal chemistry in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
Read more…

Library screening: lead-like or fragment libraries?

In this blog post, we continue discussing the need for a structural biology services company. Here, we discuss compound screening, a stage central to all drug design strategies. The quality of the compounds we identify in this process will be crucial for the discovery project.
Read more…